Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440057 | 1.00 | ACP3 (0.43) | ACP3SLC6A2TAAR1LOXL2SMN1; SMN2 | |
| SCHEMBL1465980 | 0.74 | ALDH1A1 (0.41) | ACP3SLC6A2TAAR1KIF11TSHR | |
| SCHEMBL11647115 | 0.74 | ACP3 (0.39) | ACP3SLC6A2TAAR1SMN1; SMN2HIF1A | |
| SCHEMBL5010732 | 0.72 | ACP3 (0.42) | ACP3SLC6A2TAAR1HIF1AKIF11 | |
| SCHEMBL9584692 | 0.72 | TAAR1 (0.50) | SLC6A2TAAR1LOXL2SMN1; SMN2HIF1A | |
| SCHEMBL1780460 | 0.72 | ALDH1A1 (0.39) | TAAR1KIF11TSHRALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL7677659 | 0.71 | TAAR1 (0.48) | SLC6A2TAAR1LOXL2SMN1; SMN2HIF1A | |
| SCHEMBL7853160 | 0.71 | TAAR1 (0.48) | SLC6A2TAAR1KIF11TSHRALDH1A1 | |
| SCHEMBL28289370 | 0.70 | ACP3 (0.40) | ACP3SLC6A2TAAR1KIF11MMP8 | |
| SCHEMBL29024914 | 0.69 | ALDH1A1 (0.48) | ACP3HIF1AKIF11TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014242-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | GERALD CHRISTOPHE P | 2006-01-19 | — | — | US | disclosed |
| US-6818445-B2 | ADMINISTERING COUMPOUNDS SUCH AS AROMATIC ALKYL DIAMINE DERIVATIVES AS Y5 RECEPTOR AGONIST OR ANTAGONIST TO INCREASE OR DECREASE FOOD CONSUMPTION | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-6713265-B1 | MEASURING THE BINDING OF GTP GAMMA S TO CELLS EXPRESSING Y5 RECEPTOR IN THE PRESENCE AND IN THE ABSENCE OF COMPOUND OF INTEREST | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-20040053864-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide y activity | BAYLOR COLLEGE OF MEDICINE | 2004-03-18 | — | — | US | disclosed |
| EP-1382616-A2 | Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6645774-B1 | Administering for treatment of obesity, bulimia or anorexia | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-11-11 | — | — | US | disclosed |
| EP-0732875-B1 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMA CORP (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020103123-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| EP-1007073-A4 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMA CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6316203-B1 | MONITORING ACTIVITY OF NERVOUS SYSTEM LIGAND; INCUBATE LIGAND AND TRANSFECTED CELL, DETECT AMPLIFICATION IN BINDING PROTEIN ACTIVITY, AMPLIFICATION IN BINDING PROTEIN ACTIVITY INDICATES AGONIST | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| WO-2001053477-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF BONE FORMATION VIA MODULATION OF NEUROPEPTIDE Y ACTIVITY | BAYLOR COLLEGE OF MEDICINE (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-1007073-A1 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-06-14 | — | — | EP | disclosed |
| US-5989920-A | RECEPTOR BINDING ASSAY FOR SCREENING DRUGS WHICH BIND TO HUMAN OR RAT Y5 RECEPTOR BY CONTACTING NONNEURONAL CELLS TRANSFECTED WITH VECTOR HAVING SEQUENCE CODING FOR RECEPTOR AND DETECTING BINDING; TREATMENT OF OBESITY, EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-11-23 | — | — | US | disclosed |
| US-5968819-A | FOR MODIFYING FEEDING BEHAVIOR IN CONNECTION WITH EATING DISORDERS; FOR SCREENING ANTAGONISTS, AGONISTS; FOR PROBES TO DETECT RECEPTORS; ANTISENSE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1997046250-A1 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0732875-A4 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMA CORP (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0732875-A1 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996016542-A1 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103123-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | NPY5R, NPY4R, NPY1R | ACP3 1508/4885SLC6A2 716/4885TAAR1 167/4885 |
| US-20060014242-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | NPY5R, NPY4R, NPY1R | ACP3 1502/4885SLC6A2 707/4885TAAR1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.